AcelRx Pharmaceuticals Inc (ACRX.O) Key Developments | Reuters.com
Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

2.57USD
24 Jun 2016
Change (% chg)

$-0.16 (-5.86%)
Prev Close
$2.73
Open
$2.60
Day's High
$2.65
Day's Low
$2.56
Volume
4,021,180
Avg. Vol
336,868
52-wk High
$5.88
52-wk Low
$2.56

Latest Key Developments (Source: Significant Developments)

AcelRx Pharmaceuticals announces management change
Wednesday, 5 Nov 2014 04:00pm EST 

AcelRx Pharmaceuticals Inc:Announces the departure of Richard King, the company's CEO and President.  Full Article

AcelRx Pharmaceuticals Inc 's Sufentanil sublingual tablet system study results to be presented at the International Association for the Study of Pain Meeting
Monday, 6 Oct 2014 07:00am EDT 

AcelRx Pharmaceuticals Inc:Announced a new data analysis from previously reported phase 3 studies evaluating the sufentanil sublingual tablet system (SSTS) for the treatment of moderate-to-severe acute pain will be presented at the International Association for the Study of Pain (IASP) Meeting in Buenos Aires, Argentina.Says it will present results from a phase 3, integrated analysis demonstrating ease-of-use and analgesic onset of the investigational drug/device product compared to IV patient-controlled analgesia (IV PCA).Says the integrated analysis additionally yielded statistically significant onset of analgesia differences in favor of SSTS over IV PCA as measured by pain intensity reduction from baseline, a common outcome variable.Says findings were consistent at all time points from 45 minutes through 6 hours, at which time the scores equilibrated between the two therapies.Says in general, adverse events across all treatment arms were mild to moderate in severity with comparable rates of occurrences.  Full Article

AcelRx Pharmaceuticals Inc receives complete response letter from FDA for new drug application for Zalviso
Friday, 25 Jul 2014 09:59pm EDT 

AcelRx Pharmaceuticals Inc and Grunenthal Group:Says that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).Says the company is currently reviewing the FDA's comments and requests contained in the CRL and plans to discuss these requests with the FDA.  Full Article

BRIEF-Acelrx enters controlled equity offering sales agreement

* Entered controlled equity offering sales agreement to offer and sell shares of common stock par value $0.001 per share of up to $40 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)